-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The 16th new product of this year! Shijiazhuang Fourth Pharmaceutical Group’s Aggrastat Injection has been approved.
Category:
Time：2023-03-25
On March 25, it was learned that the Class 4 chemical drug Aggrastat Injection (2 ml: 10 mg), submitted by Shijiazhuang Fourth Pharmaceutical Group, has obtained a drug registration certificate from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This marks the group’s 16th new product launched this year, signaling a strong start to its R&D innovation efforts in the first quarter.
On March 25, it was learned that the Class 4 chemical drug Aggrastat Injection (2 ml: 10 mg), submitted by Shijiazhuang Fourth Pharmaceutical Group, has obtained a drug registration certificate from the National Medical Products Administration and is deemed to have passed the consistency evaluation. This is the group’s 16th new product launched this year, marking a strong start to its R&D innovation efforts in the first quarter.
It is reported that Aggrastat injection is a thrombin inhibitor and can be used for the acute treatment of ischemic stroke within 48 hours of symptom onset.
As of now, Shijiazhuang Sihua Pharmaceutical Group has a cumulative total of 43 drug products and 55 specifications that have either passed or are deemed to have passed the consistency evaluation.
In recent years, Shijiazhuang Fourth Pharmaceutical Group has taken innovation-driven development as its guiding principle and actively implemented a “bulk pharmaceutical ingredients + finished dosage forms” development strategy. Focusing on the industrial chain, the group has strategically arranged its innovation network, comprehensively promoting research and development of high-end, complex generic drugs, innovative drugs, specialty bulk pharmaceutical ingredients, and products that have undergone consistency evaluations. The group is particularly focused on accelerating its presence and deployment in fields such as antiviral, antibacterial, cough-relief and expectorant, anti-tumor, nervous system, cardiovascular, digestive, and anesthetic therapies.
Leveraging the comprehensive package of business-friendly policies at the national, provincial, and municipal levels, the group has adopted an innovation mechanism that integrates industry, academia, research, and application. This has enabled the establishment of an innovative consortium led by enterprises, supported by universities and research institutes, and characterized by synergistic collaboration among various innovation players. As a result, the group continues to help enterprises seize new growth opportunities, build new competitive advantages, create new development patterns, generate new driving forces, and unlock fresh prospects.
Continuous innovation has enabled Shijiazhuang Fourth Pharmaceutical to establish a new paradigm of product development—“research and develop a batch, reserve a batch, and commercialize a batch”—leading to a steady accumulation of R&D achievements that are now yielding remarkable results. The company ranks among the top in China’s industry in terms of both the efficiency of developing specialty generic drugs and the number of applications submitted. Currently, the company has nearly 200 projects under development and over 100 new products awaiting approval. This increasingly robust portfolio of innovative achievements provides a stronger foundation and a powerful engine for the company’s high-quality development, helping it move toward the mid-to-high end of the industry’s value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license